FindTrial
Sign In

Hepatic vein deprivation versus transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Hepatic vein deprivation versus transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097947
Enrollment
Unknown
Registered
2025-02-27
Start date
2025-03-15
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

LVD Group:None
TACE+M+I Group:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Hepatocellular carcinoma (HCC) was diagnosed by pathology or imaging. It is suitable for right hepatectomy or extended right hepatectomy, but the future liver remnant (FLR) is insufficient. Received at least one TACE+M+I or LVD treatment; The follow-up time was not less than 3 months.

Exclusion criteria

Exclusion criteria: Concomitant liver cirrhosis

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival;Overall survival;—

Countries

China

Contacts

Public ContactHong Wu

West China Hospital, Sichuan University

drliuchang@wchscu.cn+86 189 8060 6382

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026